

Dear Colleagues,

On behalf of the National Cancer Institute (NCI) and the SeroNet Investigators Meeting Planning Committee, we would like to invite you to the second annual SeroNet Investigators Meeting, which will take place in the Natcher Conference Center (Bldg. 45) on the NIH Campus in Bethesda, Maryland (March 21-23, 2023). If pandemic travel restrictions are put in place, this meeting will take place virtually via Zoom. This meeting will bring together members of SeroNet to share cutting edge research into understanding the immune response to SARS-CoV-2 infection and/or vaccines, as well as to provide an opportunity to foster new ideas and collaborations across SeroNet. This meeting will include several themed sessions with a mixture of long and short talks, a poster session, and two panel discussions focused on Long COVID and Pandemic Preparedness. Themed sessions will be on Variants and Correlates of Immunity, Drivers of Diversity, Mucosal Immunity and Acute to Chronic Consequences of COVID.

**SeroNet Investigators Meeting Website:** [SeroNet Investigators Meeting \(Overview\)](#) | [Events Registration \(cancer.gov\)](#)

To **register**, please go to the SeroNet Investigators Meeting website and navigate to the Registration Page. There is no registration fee for attending this meeting; however, all attendees are required to individually register. Registration will close on March 1, 2023.

To **submit an abstract**, please go to the SeroNet Investigators Meeting website and navigate to the Abstract Page. Multiple abstracts for each project team are encouraged and the primary focus should be SeroNet-supported research. The deadline to submit an abstract is December 16, 2022. Submitters will be notified around January 31, 2023, if their abstract is selected for a talk or a poster. **Note that abstract submission is not coupled with registration, however, all presenters are required to register.**

We look forward to having you participate in this meeting. Please do not hesitate to contact Jennifer Rubenstein, [jennifer.rubenstein@nih.gov](mailto:jennifer.rubenstein@nih.gov), if you have any questions concerning the meeting.

Sincerely,

**The SeroNet Investigators Meeting Planning Committee**

Samantha Finstad, Ph.D., Center for Strategic Scientific Initiatives, NCI

Juli Klemm, Ph.D., Center for Strategic Scientific Initiatives, NCI

Jennifer Rubenstein, Vaccine, Immunity and Cancer Directorate, FNL

Jennifer Schwartzott, Patient Advocate

Elizabeth Norton, Ph.D., Department of Immunology & Microbiology, Tulane University

Todd Lucas, Ph.D., Michigan State University

Galit Alter, Ph.D., Ragon Institute of MGH, MIT and Harvard

Adolfo Garcia-Sastre, Ph.D., Dept of Microbiology & Medicine & Tisch Cancer Center, Icahn School of Medicine, Mount Sinai

Danielle Carrick, Ph.D., Division of Cancer Control and Population Sciences, NCI

David Zidar, MD, Ph.D., Case Western Reserve University

Ray Harris, Ph.D., Division of Cancer Treatment and Diagnosis, NCI

Stephen White, Center for Strategic Scientific Initiatives, NCI